HEPLER DOUGLAS I 4
4 · AspenBio Pharma, Inc. · Filed Aug 12, 2009
Insider Transaction Report
Form 4
HEPLER DOUGLAS I
Director
Transactions
- Sale
Common Stock
2009-08-10$2.94/sh−6,000$17,640→ 14,000 total(indirect: By Spouse)
Holdings
- 50,000
Stock Options
Exercise: $0.80From: 2005-03-28Exp: 2015-03-28→ Common Stock (50,000 underlying) - 50,000
Stock Options
Exercise: $1.33From: 2009-01-27Exp: 2019-01-27→ Common Stock (50,000 underlying) - 5,000
Common Stock
- 100,000
Stock Options
Exercise: $1.50From: 2004-03-15Exp: 2014-03-15→ Common Stock (100,000 underlying) - 50,000(indirect: By Spouse)
Stock Options
Exercise: $0.75From: 2004-08-24Exp: 2014-08-23→ Common Stock (50,000 underlying) - 50,000
Stock Options
Exercise: $1.60From: 2006-04-18Exp: 2016-04-18→ Common Stock (50,000 underlying) - 50,000
Stock Options
Exercise: $2.96From: 2007-01-24Exp: 2017-01-24→ Common Stock (50,000 underlying) - 50,000
Stock Options
Exercise: $6.63From: 2008-01-17Exp: 2018-01-17→ Common Stock (50,000 underlying)
Footnotes (5)
- [F1]Dr. Hepler disclaims beneficial ownership of the shares held by his spouse.
- [F2]These options have vested in full. This stock option grant was exempt from Section 16(b) pursuant to Rule 16b-3d.
- [F3]Options were granted pursuant to Board approval on January 24, 2007. The aggregate number of stock options granted was 50,000. One-third (16,666) of the options vest each year for three years following the date of grant. This transaction is exempt from Section 16(b) pursuant to Rule 16b-3(d).
- [F4]Options were granted pursuant to Board approval on January 17, 2008. The aggregate number of stock options granted was 50,000. One third (16,666) of the options vest each year for three years following the date of grant. This transaction is exempt from Section 16(b) pursuant to Rule 16b-3(d).
- [F5]Options were granted pursuant to Board approval on January 27, 2009. The aggregate number of stock options granted was 50,000. One third (16,666) of the options vest each year for three years following the date of grant. This transaction is exempt from Section 16(b) pursuant to Rule 16b-3(d).